Beroni Group (FRA:6B9) Other Stockholders Equity: €1.86 Mil (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:6B9 Beroni Group Ltd FRA:6B9
57 GF Score
Price €0.01
View Full Analysis

What is Beroni Group Other Stockholders Equity?

Beroni Group FRA:6B9 57 Other Stockholders Equity is €1.86 Mil as of Jun. 2024. GuruFocus rates FRA:6B9 with a GF Score™ of 57/100.

Beroni Group's Other Stockholders Equity for the quarter that ended in Jun. 2024 was €1.86 Mil.

Beroni Group's quarterly Other Stockholders Equity declined from Jun. 2023 (€1.86 Mil) to Dec. 2023 (€1.85 Mil) but then increased from Dec. 2023 (€1.85 Mil) to Jun. 2024 (€1.86 Mil).

Beroni Group's annual Other Stockholders Equity increased from Dec. 2021 (€0.00 Mil) to Dec. 2022 (€1.92 Mil) but then declined from Dec. 2022 (€1.92 Mil) to Dec. 2023 (€1.85 Mil).

Beroni Group Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Beroni Group's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beroni Group Other Stockholders Equity Chart

Beroni Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Stockholders Equity
Get a 7-Day Free Trial -0.00 0.72 0.00 1.92 1.85

Beroni Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 1.92 1.86 1.85 1.86
FRA:6B9
57GF Score
Beroni Group Ltd FRA:6B9
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beroni Group Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €1.86 Mil mean?
Beroni Group (FRA:6B9) has a Other Stockholders Equity of €1.86 Mil as of Jun. 2024. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Beroni Group and its competitors.
Is Beroni Group's Other Stockholders Equity too high?
Beroni Group's current Other Stockholders Equity is €1.86 Mil. Overall, Beroni Group has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's Other Stockholders Equity compare to PNXP and CRYM?
Beroni Group's Other Stockholders Equity of €1.86 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Beroni Group and its competitors. Beroni Group's current Other Stockholders Equity is €1.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (FRA:6B9) has a current Other Stockholders Equity of €1.86 Mil. The current Other Stockholders Equity is €1.86 Mil. Beroni Group's overall GF Score™ is 57/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Beroni Group (FRA:6B9), the current Other Stockholders Equity is €1.86 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beroni Group Business Description

Address 175 Pitt Street, Level 16, Sydney, NSW, AUS, 2000
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
57GF Score

Get the complete analysis for FRA:6B9

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price